What type of study is this?

September 10, 2025

Use of tocilizumab to treat IgA nephropathy complicated by idiopathic multicentric Castleman disease: a case report

View Full Paper

Ask AI

Bookmark

After treatment with tocilizumab, serum creatinine improved from 1.45 to 1.23 mg/dL, indicating enhanced renal function.
Proteinuria decreased significantly from 1.18 to 0.17 g/day following tocilizumab therapy in the patient with IgA nephropathy.
Tocilizumab lowered serum VEGF levels from 1557 to 702 pg/mL, suggesting a potential mechanism for renal protection.
This case contributes to understanding IL-6 inhibition in managing renal involvement in iMCD complicated with IgA nephropathy.

No takes yet. Share an insight, caveat, or question.

Case report shows improvement in renal function and proteinuria in iMCD patients, highlighting IL-6's role.

Komeno et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark